Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TSC-203-A0201 · TSC-203

Other · developed by TScan Therapeutics

Phase 1 Most advanced trial
TCRX Developer
1 Registered trials

What is TSC-203-A0201?

TSC-203-A0201 is an investigational agent studied as a monotherapy and in combination with TSC-204-A0101, TSC-201-B0702 and TSC-202-A0201 in escalating doses. It is being studied in HPV-related cancers, including cervical cancer, head and neck cancer and other HPV-associated malignancies, as well as melanoma, non-small cell carcinoma and ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TSC-203
Drug type
Other
Therapy area
Oncology
Developer
TScan Therapeutics, Inc. (TCRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05973487 Phase 1 Head and Neck Cancer Active not recruiting TCRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Anogenital CancersCervical CancerHead and Neck CancerHPV - Anogenital Human Papilloma Virus InfectionHPV Positive Oropharyngeal Squamous Cell CarcinomaHPV-Associated Vaginal AdenocarcinomaHPV-Related AdenocarcinomaHPV-Related Adenosquamous CarcinomaHPV-Related CarcinomaHPV-Related Cervical CarcinomaHPV-Related MalignancyHPV-Related Squamous Cell CarcinomaMelanomaNon-small Cell Carcinoma

More from TScan Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TCRX page.

Follow TCRX, the company behind TSC-203-A0201

See TCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TCRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.